1(S)-Phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 3(R)-quinuclidinyl ester
SOLIFENACIN
CAS: 180272-14-4
Molecular Formula: C23H26N2O2
1(S)-Phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 3(R)-quinuclidinyl ester - Names and Identifiers
1(S)-Phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 3(R)-quinuclidinyl ester - Physico-chemical Properties
| Molecular Formula | C23H26N2O2 |
| Molar Mass | 362.46 |
| Density | 1.24±0.1 g/cm3(Predicted) |
| Boling Point | 505.5±50.0 °C(Predicted) |
| pKa | 9.03±0.33(Predicted) |
1(S)-Phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 3(R)-quinuclidinyl ester - References
| indication | for the treatment of urinary incontinence and/or urinary frequency and urgency in patients with overactive bladder. |
| pharmacological action | solifenacin mainly works by blocking receptors in the tissues of the bladder wall, as a result, the latter cannot complete the inositol triphosphate diacylglycerol (double Messenger conduction pathway, which inhibits the contraction of detrusor muscle and alleviates urinary frequency caused by overactive bladder, symptoms such as urinary urgency and urge incontinence. |
| adverse reactions | due to the pharmacological effects of solifenacin, this product may cause light (usually), moderate anticholinergic side effects, the frequency of their occurrence is dose-dependent. The most common adverse reaction reported was dry mouth. The incidence was 11% in patients treated with 5mg once daily, 22% in patients treated with 10mg once daily, and 4% in patients treated with placebo. Usually the degree of dry mouth is mild, occasionally patients need to interrupt treatment. Overall, adherence to medication was very high (approximately 99%), with approximately 90% of patients treated with Seroquel completing the 12-week study. |
| precautions | should be used with caution in the following patients: 1, gastrointestinal obstructive disease; Risk of weakening of gastrointestinal peristalsis; Severe renal dysfunction (creatinine clearance ≤ 30ml/min), the dose of these patients should not exceed 5mg once daily, moderate liver dysfunction (child-pugh score 7-9), the dosage of these patients should not exceed 5mg once a day; 5. At the same time, ketoconazole and other potent cytochrome p4503a4 inhibitors should be used; 6, hiatal hernia/gastro-oesophageal reflux and/or taking medications that can cause or aggravate Esophagitis (e. G., diphosphonium compounds);7, the safety and efficacy of medication in patients with neurogenic detrusor overactivity have not been established; 8. Patients with hereditary galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption should not use this product; 9, the maximum efficacy of the product can be determined as early as 4 weeks after taking the drug; 10, the impact on driving and operating machinery: like other anticholinergic drugs, solifenacin may cause blurred vision, drowsiness and fatigue (less common) May have a negative impact on driving and mechanical operation. |
Last Update：2024-04-09 21:21:28
Supplier List
View History